Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma

Nuclear Medicine Review

Volumn 8, Issue 2, 2005, Pages 111-115

  Ambrosini, Valentina ^a   Rubello, Domenico ^b   Nanni, Cristina ^a   Farsad, Mohsen ^a   Castellucci, Paolo ^a   Franchi, Roberto ^a   Fabbri, Mario ^a   Rampin, Lucia ^b   Crepaldi, Giorgio ^c   Al Nahhas, Adil ^d   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b S MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

18F FDG PET CT fusion imaging; CT scan; Malignant pleural mesothelioma; Staging; Treatment planning

Indexed keywords

ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE PROCESSING; IMAGING SYSTEM; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MALE; MANAGED CARE; MEDIASTINUM LYMPH NODE; PLEURA MESOTHELIOMA; THICKNESS; TREATMENT PLANNING; TUMOR LOCALIZATION; WHOLE BODY SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMAGE ENHANCEMENT; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 30944438115     PISSN: 15069680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Flores RM. Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience. Lung Cancer 2005; 49: S71-S74.
2. Wang ZJ, Reddy GP, Gotway MB et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics 2004; 24: 105-119.
3. Yakirevich E, Sova Y, Drumea K, Bergman I, Quitt M, Resnick MB. Peripheral lymphadenopathy as the initial manifestation of pericardial mesothelioma: a case report. Int J Surg Pathol 2004; 12: 403-405.
4. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999; 79: 666-672.
5. Pistolesi M, Rusthoven J. Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies. Chest 2004; 126: 1318-1329.
6. Serman DH, Recio A, Vachani A et al. Long-term follow-up of patients with malignant mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 2005; 11: 7444-7453.
7. Lee TT, Everett DL, Shu HK et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2002; 124: 1183-1189.
8. Singhal S, Kaiser LR. Malignant mesothelioma: options for management. Surg Clin North Am 2002; 82: 797-831.
9. Hoberkorn U. Positron emission tomography in the diagnosis of mesothelioma. Lung Cancer 2004; 45: S73-S76.
10. Nanni C, Castellucci P, Farsad M et al. Role of 18F-FDG PET for evaluating malignant pleural mesothelioma. Cancer Biother Radiopharm 2004; 19: 149-154.
11. Flores RM. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer 2005; 49: S27-S32.
12. Cohade C, Wahl RL. Applications of positron emission tomography//computed tomography image fusion in clinical positron emission tomography-clinical use, interpretation methods, diagnostic improvements. Semin Nucl Med 2003; 33: 228-237.
13. Erasmus, JJ, Truong MT, Smythe WR et al. Integrated computed tomography-positron emission tomography in patients with potentially resecable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg 2005; 129: 1364-1370.
14. Kluetz PG, Meltzer CC, Villemagne VL et al. Combined PET/CT imaging in oncology. Impact on patient management. Clin Positron Imaging 2000; 3: 223-230.
15. Sobin LH, Wittekind C. UICC, TNM, Classification of malignant tumours, 5th ed, Wiley-Liss, New York 1997.